0001004878-17-000252.txt : 20171207
0001004878-17-000252.hdr.sgml : 20171207
20171206181004
ACCESSION NUMBER: 0001004878-17-000252
CONFORMED SUBMISSION TYPE: 424B3
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20171207
DATE AS OF CHANGE: 20171206
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 424B3
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-219368
FILM NUMBER: 171243142
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
424B3
1
prosupp1510000dec-17.txt
Filed pursuant to Rule 424(b)(3)
Registration No. 333-219368
PROSPECTUS SUPPLEMENT
(To prospectus dated August 3, 2017)
CEL-SCI CORPORATION
On June 22, 2017 the Company sold convertible notes in the principal amount
of $1,510,000 to private investors. Holders of notes in the principal amount of
$450,700 subsequently converted these notes into shares of the Company's common
stock.
On November 2, 2017 holders of convertible notes in the remaining principal
amount of $1,059,300 agreed to extend the maturity date of their notes to
September 21, 2018.
In consideration for the extension of the maturity date of the notes, the
Company issued a total of 446,748 Series RR warrants to the note holders that
agreed to the extension. Each Series RR warrant entitles the holder to purchase
one share of the Company's common stock at a price of $1.65 per share at any
time on or before October 30, 2022.
Prospectus Supplement dated December 6, 2017